

Spirometry Workshop

Katherine Macpherson
Senior Respiratory Scientist

Department of Respiratory & Sleep Medicine

Derek Figurski
Laboratory Manager



Learning Outcomes

- ▶ Understand the indications & contraindications for spirometry testing
- ▶ Perform spirometry within clinical guidelines
- ▶ Understand quality assurance principles for spirometry
- ▶ Understand spirometry interpretation



Introduction to Spirometry

Derek Figurski
Laboratory Manager
Department of Respiratory & Sleep Medicine
Canberra Hospital



Spirometry Overview

- ▶ A measurement of airflow and lung vital capacity during a forced expiratory manoeuvre from full inspiration
- ▶ Different ways of describing...
 - ▶ Dynamic lung volumes
 - ▶ Maximal flow rates at different lung volumes
 - ▶ The mechanical properties of the lungs
- ▶ Measured using a spirometer



Why spirometry?

- ▶ To detect and quantify extent of airways obstruction and its alternative – lung restriction
- ▶ Spirometry is recommended by:
 - ▶ National Asthma Council Australia
 - ▶ Lung Foundation Australia
 - ▶ Thoracic Society of Australia and New Zealand



Peak Expiratory Flow (PEF)


- ▶ PEF measured by a peak flow meter is no substitute for full spirometry
- ▶ PEF doesn't provide sufficient information to assess lung function
- ▶ PEF is often done in general practice and is sometimes confused with spirometry




Definitions

- ▶ **FEV₁:**
 - ▶ Volume expired in the first second of a forced maximal expiration initiated after maximal inspiration
- ▶ **FVC**
 - ▶ maximum volume of air which can be expired with
 - ▶ maximal force (after a maximal inspiration) during a
 - ▶ forced manoeuvre
- ▶ **FEV₁/FVC (FEV₁/FVC ratio or Forced Expiratory Ratio)**
 - ▶ FEV₁ expressed as a percentage of the FVC
- ▶ **PEF**
 - ▶ maximal expiratory flow achieved during the forced
 - ▶ expiratory manoeuvre (L/s)
- ▶ **FEF_{25-75%} (forced expiratory flow between 25% and 75% of FVC):**
 - ▶ Average expiratory flow during the middle half of the FVC manoeuvre
- ▶ **FET (forced expiratory time):**
 - ▶ Time required to perform the FVC manoeuvre

Volume-Time (Spirogram)



Flow-Volume Curve



All volumes and flows reported at
Body Temperature and Pressure Saturated (BTPS)

BTPS

- ▶ All volumes and flows reported at Body Temperature and Pressure Saturated (BTPS)
- ▶ When “warm” air is expelled into a “cold” spirometer, the volume recorded by the spirometer is less than that blown out of the lungs
 - ▶ Gas shrinkage (Charles’ Law)
 - ▶ Condensation of water vapour (vapour pressure falls when gas cools)



Considerations when selecting a spirometer

- ▶ Meets the ATS/ERS spirometer performance criteria
- ▶ Ease of use and easy to follow instructions
- ▶ Provides a real-time graphic display of the manoeuvre (large enough to see)
- ▶ Accurate (can be calibrated or accuracy validated)
- ▶ Relevant predicted values
- ▶ Hardcopy of the results possible



Johns DP, Burtson D., Swanney MP. "Spirometer Users' and Buyers' Guide" National Asthma Council Australia, 2015 Available at: <http://www.nationalasthma.org.au/health-professionals/spirometry-resources/spirometer-users-buyers-guide>



Considerations when selecting a spirometer

- ▶ Reliable with low maintenance requirements
- ▶ Flow sensor is disposable or easily cleaned/disinfected
- ▶ Provision of technical support and supplies
- ▶ Easy access to regular servicing (e.g.doesn't need to go overseas)
- ▶ Links with clinical software
- ▶ Price (including consumables)

Johns DP., Burtson D., Swanney MP. "Spirometer Users' and Buyers' Guide" National Asthma Council Australia, 2015 Available at:
<http://www.nationalasthma.org.au/health-professionals/spirometry-resources/spirometer-users-buyers-guide>



Indications & Contraindications

Katherine Macpherson
Senior Respiratory Scientist
Department of Respiratory & Sleep Medicine
Canberra Hospital



Indications for Spirometry

▶ **Diagnostic:**

- ▶ To evaluate symptoms, signs or abnormal laboratory tests;
- ▶ To measure the effect of disease on respiratory function;
- ▶ To screen individuals at risk of having respiratory disease;
- ▶ To assess pre-operative risk;
- ▶ To assess prognosis;



Indications for Spirometry

▶ **Monitoring:**

- ▶ To assess therapeutic intervention;
- ▶ To describe the course of diseases that affect respiratory function;
- ▶ To monitor people exposed to injurious agents;
- ▶ To monitor for adverse reactions to drugs with known respiratory toxicity;



Indications for Spirometry

- ▶ **Disability/impairment evaluations:**
 - ▶ To assess subjects as part of a rehabilitation programme;
 - ▶ To assess risks as part of an insurance evaluation;
 - ▶ To assess individuals for legal reasons;



Indications for Spirometry

- ▶ **Public Health**
 - ▶ Epidemiological surveys;
 - ▶ Derivation of reference equations;
 - ▶ Clinical research.



Contraindications

- ▶ **Absolute Contraindication:**
 - ▶ Could cause trauma, injury or death to patient if undertaken.
Tests are not to be performed.
- ▶ **Relative Contraindication:**
 - ▶ Require requesting physician/healthcare expert to judge when it is safe and appropriate to perform breathing test.



Importance?

- ▶ **Risk management:**
 - ▶ The likelihood of an event occurring;
 - ▶ The severity of the consequences of an event occurring.

- ▶ Benefits to patient of obtaining test results need to outweigh risks.



Potential Harm

- ▶ Requires maximal effort which may result in:
 - ▶ Transient breathlessness
 - ▶ Cough
 - ▶ Light headedness/ Syncope
 - ▶ Chest pain
 - ▶ Oxygen desaturation
 - ▶ Incontinence
 - ▶ Headache
- ▶ In patients with poorly controlled asthma:
 - ▶ Forced manoeuvre can also induce bronchospasm
 - ▶ Progressive decrease in FEV₁ with successive blows



Potential Harm

- ▶ Maximal pressures generated in thorax impact on thoracic/abdominal tissues/organs;
- ▶ Large swings in BP causing stresses on other tissues in body (eg limbs, head);
- ▶ Expansion of chest wall and lungs;
- ▶ Active communicable diseases.



Current recommendations

- ▶ **1996, American Association for Respiratory Care:**
 - ▶ Haemoptysis of unknown cause;
 - ▶ Pneumothorax;
 - ▶ Unstable cardiovascular status;
 - ▶ Thoracic, abdominal or cerebral aneurysm;
 - ▶ 'Recent' eye surgery;
 - ▶ Presence of acute illness/symptom;
 - ▶ Recent abdominal or thoracic surgery.

- ▶ **2005, ATS/ERS, General Considerations for Lung Function:**
 - ▶ Myocardial Infarction within 1 month
 - ▶ Chest/abdominal pain of any cause
 - ▶ Oral or facial pain exacerbated by mouthpiece;
 - ▶ Stress incontinence;
 - ▶ Dementia/confused state



Absolute Contraindications

Do not proceed with test if any of these criteria are met.

- ▶ Myocardial Infarction (wait 1 month);
- ▶ AAA- ascending aortic aneurysms (>6cms);
- ▶ Respiratory embolism;
- ▶ Angina (unstable);
- ▶ Severe hypertension (systolic >200mmHg, diastolic >120mmHg) (Measure before tests if suspected).



Relative Contraindications

Use clinical judgement before proceeding with test. Seek medical advice if any of these criteria are met

- ▶ Thoracic/abdominal surgery (see table below for examples);
- ▶ Brain, eye, ear, ENT surgery (see table below for examples);

Surgery Type	Recommendations
Abdominal (conventional or laparotomy)	1 week
Caesarean section (uncomplicated)	6-8 weeks
Laser eye surgery	1 week
Brain surgery	3-6 weeks
Vascular surgery (especially lower limb)	4-6 weeks

- ▶ Pneumothorax (wait 2 weeks);
- ▶ Haemoptysis;
- ▶ Subjects with an inability to understand instructions, confused/demented subjects or subjects unable to provide consent;
- ▶ Subject discomfort – vomiting, diarrhoea, cold sores, common cold; (wait until main symptoms abate);
- ▶ Infection control issue – norovirus, TB, flu (wait until main symptoms abate);
- ▶ *Chest or abdominal pain of any cause;
- ▶ *Oral or facial pain exacerbated by a mouthpiece;
- ▶ *Stress incontinence.

Infective Contraindications

1. Harm to patients performing the test;
2. Pain or discomfort to patients (vomiting etc);
3. Harm to staff or other patients;
4. Redundant results because of submaximal effort;
5. Results do not contribute to clinical plan.

Performing Spirometry

Derek Figurski
Laboratory Manager
Department of Respiratory & Sleep Medicine
Canberra Hospital



Patient Instructions

- ▶ **Activities that should preferably be avoided prior to lung function testing:**
 - ▶ Performing vigorous exercise within 30 min
 - ▶ Smoking within 1hr
 - ▶ Consuming alcohol within 4hr
- ▶ **Do not wear clothing that substantially restricts full chest and abdominal expansion**




Patient Instructions

- ▶ **Ideally:**
 - ▶ No short acting β -agonist (SABA) within 4hrs of test
 - ▶ No long acting β -agonist (LABA) used within 12hrs (e.g. efometerol); or 24hrs (e.g. indacaterol) of test
 - ▶ No long acting anti muscarinic/anticholinergics within 24hrs of test
- ▶ If any bronchodilator medications have been taken, note time last used

Pre Test Preparation

- ▶ Wash hands
- ▶ Prepare the spirometer
- ▶ Enter patient demographics:
 - ▶ Height and weight without shoes, age, gender and ethnic origin
- ▶ Ask about smoking, recent illness and medication use
- ▶ Ensure subject is sitting up tall with their legs uncrossed. Feet should be flat on the floor.
- ▶ Explain procedure to patient. Demonstrate if necessary.



Open Circuit VS Closed Circuit

- ▶ **Open Circuit:**
 - ▶ Patient performs only expiratory portion of manoeuvre on spirometer
- ▶ **Closed Circuit:**
 - ▶ Patient performs entire manoeuvre (inspiratory and expiratory portions) on spirometer



Method – Open Circuit

- ▶ **Patient should:**
 - ▶ Inhale completely and rapidly away from the mouthpiece;
 - ▶ Seal lips around mouthpiece and blast out as hard and fast as possible;
 - ▶ Continue blowing until lungs are empty (>6seconds and plateau achieved for adults).



Method – Closed Circuit

- ▶ **Patient should:**
 - ▶ Seal lips around mouthpiece and inhale completely and rapidly;
 - ▶ Blast out as hard and fast as possible;
 - ▶ Continue blowing until lungs are empty (>6seconds and plateau achieved for adults).



Test Performance

- ▶ Manoeuvre should be repeated until 3 acceptable and repeatable efforts are obtained
 - ▶ Usually no more than 8 attempts
- ▶ Manoeuvre must be “Acceptable” and “Repeatable”




Acceptable

- ▶ Subject must have taken a full breath in before blowing out;
- ▶ Subject must blow all the way out (achieve a plateau);
- ▶ The forced expiratory manoeuvre must be:
 - ▶ Immediate (no hesitation);
 - ▶ Maximal Effort;
 - ▶ Be smooth and continuous (ie free from cough or glottic closure)



Repeatable

- ▶ Obtain at least **3** acceptable blows
- ▶ The two largest values for FEV_1 should be within 150 mL of each other
- ▶ The two largest values for FVC should be within 150 mL of each other
 - ▶ If FVC is \leq IL should be within 100mL of each other



Practical Session...



Quality Assurance

Katherine Macpherson
Senior Respiratory Scientist
Department of Respiratory & Sleep Medicine
Canberra Hospital

Quality Control

▶ Calibration

- ▶ Testing with known volume at different flow rates;
- ▶ 3L calibration syringe, read $3L \pm 0.5\%$ (2.895 – 3.105 L* (ATPS))

▶ Biological Control

- ▶ Known healthy test subject with >10 data points
- ▶ Plot over time

▶ Personnel Training

- ▶ Regular & ongoing



Quality Control

▶ Equipment Maintenance (must keep log/records)


- ▶ Calibration check (or validation of accuracy)
- ▶ Cleaning and disinfection procedures
- ▶ Electrical operation and safety checks
- ▶ Mechanical operation and safety checks
- ▶ Software/database maintenance and back-up



Quality Control

- ▶ Infection Control
 - ▶ Need to provide safe equipment and environment
 - ▶ Wipe down spirometer between each patient
 - ▶ Barrier filters reduce risk of cross-infection – single patient use where possible
 - ▶ Operator to stand clear to avoid potential airborne/droplet transmission

Measurement Procedures




Acceptable

- ▶ Subject must have taken a full breath in before blowing out;
- ▶ Subject must blow all the way out (achieve a plateau);
- ▶ The forced expiratory manoeuvre must be:
 - ▶ Immediate (no hesitation);
 - ▶ Maximal Effort;
 - ▶ Be smooth and continuous (ie free from cough or glottic closure)




Repeatable

- ▶ Obtain at least **3** acceptable blows
- ▶ The two largest values for FEV_1 should be within 150 mL of each other
- ▶ The two largest values for FVC should be within 150 mL of each other
 - ▶ If FVC is $\leq 1L$ should be within 100mL of each other



Consistent Effort


Not maximal effort



PEF 100 L/min

FEV1 1.50 L

Maximal effort



PEF 150 L/min

FEV1 0.90 L



Causes of Poor Quality Spirometry

- ▶ Lack of tester knowledge/experience
- ▶ Inaccurately measured or entered patient details (i.e. age, gender, height and ethnicity)
- ▶ Poorly maintained or calibrated spirometer
- ▶ Results not repeatable




Patient-Related Problems


- ▶ Lack of patient understanding/compliance
- ▶ Patient not completely 'full' at the start
- ▶ Delay in initial effort
- ▶ Premature termination of blow
- ▶ Tongue occlusion
- ▶ Glottic closure
- ▶ Cough – especially during the first second
- ▶ Vocalisation during the blow
- ▶ Poor posture
- ▶ Leak (e.g. around mouthpiece)



Troubleshooting: poor spiograms



Troubleshooting: poor flow-volume




Interpretation of Spirometry

Derek Figurski
Laboratory Manager
Department of Respiratory & Sleep Medicine
Canberra Hospital

W's Spirometry

	Pre			Post			LLN	ULN
	Pred	Actual	%Pred	Actual	%Pred	%Chng		
--- SPIROMETRY ---								
FVC (L)	4.18	2.82	67	3.87	92	+36	3.17	5.19
FEV1 (L)	3.21	1.17	36	2.11	65	+81	2.37	4.05
FEV1/FVC (%)	75	41	55	55	72	+32	63	87
FEF 25-75% (L/sec)	3.21	0.43	13	1.24	38	+184	1.49	4.93
FEF Max (L/sec)	8.17	3.40	41	5.18	63	+52	6.17	10.17
Expiratory Time (sec)		10.90			11.34			+4
Back Extrap Vol (L)		0.06			0.07			+28





What does this tell you??




Predicted Values

POPULATION SAMPLE




NORMAL DISTRIBUTION



- In disease a ↓ in FEV₁ usually occurs therefore we want to determine LLN of normal
- Margin of error is usually 5% and the LLN is calculated by: mean ± 1.64S (5% of healthy subjects will have values below the LLN)


Predicted Values

- ▶ Cannot say that a result is 'normal', only can say that it is 'within normal limits' since we do not know an individual's starting point
- ▶ It is more valuable to compare results with previous results than with predicted values



- Note large inter-individual variability of normal sample suggestion of $\pm 20\%$
- Intra-individual variability of $\pm 5\%$ with well trained patient

Interpretation algorithm




Spirometry Interpretation

- Use the **FEV₁/FVC** ratio to **detect obstruction**
- Use **FEV₁ as % predicted** to grade severity of obstruction
- Use **FVC** to **assess restriction**
 - Low FVC (VC) in presence of significant obstruction does not necessarily indicate restriction
 - Need to confirm and quantify restriction with measurement of Total Lung Capacity
- A low FEF_{25-75%} in the presence of normal FEV₁ can be used to detect 'early airflow obstruction' but only if FVC is within normal limits.
 - Lower limit of normal FEF_{25-75%} is about 60% predicted
- **Bronchodilator Reversibility**
Significant reversibility is a **12% (or greater)** improvement in FEV₁ and in addition an increase of **at least 200 ml**




Obstructive disorders (airflow limiting)

- In obstructive respiratory disorders, airflow is reduced as a result of airway narrowing (unable to blow out quickly)
- Reduced maximum expired flows are due to:
 - airway lumen narrowing by mucus (**bronchitis**)
 - Reactive airways caused by airway wall thickening/inflammation (**asthma**)
 - Loss of lung elastic recoil (**emphysema/COPD**)



Restrictive disorders (volume limiting)


- In restrictive disorders there is a reduction in the FVC
- This can be either **intrapulmonary** or **extrapulmonary**



Hyatt, Scanlon & Nakamura 2003




Abnormal Flow Volume Loops



Upper Airway Physiology

- ▶ Variable extrathoracic lesions
 - ▶ Vocal cord paralysis
 - ▶ Subglottic stenosis
 - ▶ Neoplasm (primary hypopharyngeal or tracheal, metastatic from primary lesion in lung)
 - ▶ Goitre
- ▶ Variable intrathoracic lesions
 - ▶ Tumour of lower trachea (below sternal notch)
 - ▶ Tracheomalacia
- ▶ Fixed lesions
 - ▶ Fixed neoplasm in central airway
 - ▶ Vocal paralysis with fixed stenosis
 - ▶ Fibrotic strictures



Bronchodilator Reversibility

- ▶ To assess bronchodilator (BD) reversibility:
 - ▶ Perform pre-BD spirometry
 - ▶ Administer BD, e.g. 4 separate puffs salbutamol via MDI and spacer
 - ▶ Wait 10min
 - ▶ Repeat spirometry
- ▶ If any bronchodilator medications have been taken, note time last used

Bronchodilator Reversibility

- ▶ **FEV₁** is the most commonly used index to quantify reversibility
- ▶ Positive BD response is an increase in :
 - ▶ FEV₁ (or FVC) of ≥12% (% improvement)
 - ▶ and FEV₁ of ≥200 mL (absolute change)

$$\% \text{ Improvement in FEV}_1 = 100 \times \frac{\text{FEV}_1 (\text{post-BD}) - \text{FEV}_1 (\text{baseline})}{\text{FEV}_1 (\text{baseline})}$$

$$\text{Absolute change in FEV}_1 = \text{post-BD FEV}_1 - \text{baseline FEV}_1$$



References

- ▶ Johns DP, Burtson D, Swanney MP. "Spirometer Users' and Buyers' Guide" National Asthma Council Australia, 2015 Available at: <http://www.nationalasthma.org.au/health-professionals/spirometry-resources/spirometer-users-buyers-guide>
- ▶ Johns DP & Pierce R. "Spirometry: The Measurement and Interpretation of Ventilatory Function in Clinical Practice", TSANZ, 2008, Available at: <http://www.nationalasthma.org.au/health-professionals/spirometry-resources/spirometry-handbook>
- ▶ Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R et al; "ATS/ERS Task Force: Standardisation of lung function testing. Number 1 in this series: General considerations for lung function testing." European Respiratory Journal, 26:153-161, 2005.
- ▶ Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R et al; "ATS/ERS Task Force: Standardisation of lung function testing. Number 2 in this series: Standardisation of spirometry." European Respiratory Journal, 26:319-338, 2005.

